ANAB Nov 2024 17.500 call
| Previous close | 10.09 |
| Open | 10.09 |
| Bid | 6.60 |
| Ask | 10.70 |
| Strike | 17.50 |
| Expiry date | 2024-11-15 |
| Day's range | 8.35 - 10.09 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%
Shareholders in AnaptysBio, Inc. ( NASDAQ:ANAB ) may be thrilled to learn that the analysts have just delivered a major...
ZacksAnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of -6.49% and 57.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireAnaptys Announces First Quarter 2024 Financial Results and Provides Business Update
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectivelyIND submissions for ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) anticipate
